Lupin Limited (BOM:500257)
India
· Delayed Price · Currency is INR 2,091.95
+11.35 (0.55%)
At close: Dec 4, 2025
Lupin Revenue
Lupin had revenue of 70.48B INR in the quarter ending September 30, 2025, with 24.23% growth. This brings the company's revenue in the last twelve months to 247.51B, up 15.49% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B with 13.48% growth.
Revenue (ttm)
247.51B
Revenue Growth
+15.49%
P/S Ratio
3.87
Revenue / Employee
10.31M
Employees
24,006
Market Cap
958.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,996.29B |
| HDFC Bank | 2,683.70B |
| Bharti Airtel | 1,946.14B |
| Tata Consultancy Services | 2,576.88B |
| ICICI Bank | 1,909.34B |
| State Bank of India | 3,571.95B |
| Infosys | 1,748.84B |
| Bajaj Finance | 406.39B |
Lupin News
- 1 day ago - Lupin receives U.S. FDA tentative approval for generic Siponimod tablets - Business Upturn
- 2 days ago - Lupin signs exclusive licensing agreement with Valorum Biologics for biosimilar Armlupeg in the US - Business Upturn
- 5 days ago - Lupin gets U.S. FDA Approval for Biosimilar Armlupeg - Business Upturn
- 20 days ago - Lupin’s Nagpur Unit-1 clears USFDA Pre-Approval inspection with zero observations - Business Upturn
- 24 days ago - Lupin unveils dedicated oncology block at Vizag to boost global CDMO capabilities - Business Upturn
- 26 days ago - Lupin share: Morgan Stanley maintains equalweight, Jefferies buy; brokerages see up to 16.8% upside on strong US business and margin guidance - Business Upturn
- 4 weeks ago - Lupin Ltd (BOM:500257) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth ... - GuruFocus
- 4 weeks ago - Lupin’s Pune Bioresearch Centre clears US FDA inspection with zero observations - Business Upturn